Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;3(4):235-240.
doi: 10.1016/j.jpha.2012.12.007. Epub 2012 Dec 28.

Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry

Affiliations

Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry

Jin-Feng Zhang et al. J Pharm Anal. 2013 Aug.

Abstract

A highly sensitive ultra-high-performance liquid chromatographic-tandem mass spectrometry (UPLC/MS/MS) method was developed for the quantification of the synthetic peptide drug of exenatide in monkey plasma. Sample preparation was carried out by solid-phase extraction (SPE), and bivalirudin was used as the internal standard (IS). An excellent chromatographic separation was obtained on a reversed-phase C18 column with a gradient elution. Detection utilized a Qtrap 5500 system operated in the positive ion mode with multiple reaction monitoring (MRM). The proposed method was validated by assessing the specificity, linearity, intra- and inter-day precision and accuracy, recovery, and stability. The method resulted in a linear calibration range of 0.10-30 ng/mL, extracting with only 50 μL monkey plasma aliquots. The intra- and inter-day precisions (as relative standard deviation) were less than 7.5% and 9.6%, respectively. The method could be successfully utilized for the pharmacokinetic study of exenatide in monkeys following a single subcutaneous injection of Byetta.

Keywords: Exenatide; Monkey; Pharmacokinetics; Plasma; Quantitation; UPLC/MS/MS.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The product ion scans of [M+4H]4+ for exenatide (A) and [M+2H]2+ for bivalirudin (B).
Fig. 2
Fig. 2
Representative MRM chromatograms of exenatide (m/z 1047.4→396.3) in four different animals blank plasma (human, monkey, dog and rat).
Fig. 3
Fig. 3
Representative MRM chromatograms of exenatide and bivalirudin in monkey plasma. (A) Blank plasma; (B) blank plasma spiked with 0.1 ng/mL of exenatide (I) and 8.5 ng/mL bivalirudin (II); (C) plasma sample from a monkey volunteer 15 min of exenatide after the subcutaneous injection of exenatide (5 μg for each monkey).
Fig. 4
Fig. 4
Plasma concentration–time profile of subcutaneous injection of exenatide (5 μg for each monkey) to healthy monkey. Data are mean±SD for three monkeys (three males).
None

Similar articles

Cited by

References

    1. Flatt P.R., Bailey C.J., Green B.D. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr. Drug Metab. 2009;10:125–137. - PubMed
    1. Srinivasan B.T., Jarvis J., Khunti K. Recent advances in the management of type 2 diabetes mellitus: a review. Postgrad. Med. J. 2008;84:525–526. - PubMed
    1. Freeman J.S. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo. Clin. Proc. 2010;85(12):7–9. - PMC - PubMed
    1. Aroda V.R., Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab. Res. Rev. 2011;27:528–529. - PubMed
    1. Jones R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int. J. Clin. Pract. 2010;64:1403–1414. - PubMed

LinkOut - more resources